SS-31

SS-31 is a mitochondria-targeted antioxidant peptide that is being investigated for its potential in treating diseases linked to mitochondrial dysfunction by reducing oxidative damage. It has been evaluated in animal models and clinical trials for mitochondrial myopathy and metabolic dysfunction.

• Reduces mitochondrial oxidative stress
• Improves mitochondrial function
• Targets cardiolipin in the inner mitochondrial membrane
• Preserves ATP production and mitochondrial integrity under stress

• unit: mg

  low dose: 0.05

  frequency: Single IV infusion (clinical/research setting)

  high dose: 0.25

  standard dose: 0.1

  administration route: Intravenous (IV)

• unit: mg

  low dose: 20

  frequency: Once daily

  high dose: 40

  standard dose: 40

  administration route: Subcutaneous (SQ)

• Typical cycle length is 4–12 weeks, with reassessment of mitochondrial function after the cycle.
• Cycle: 4–6 weeks on, then 2–4 weeks off Morning dosing is most common. Some researchers use 0.1–1mg daily for microdosing. Often used as a primer before MOTS-c.

common: ["~80% of patients experience mild injection-site reactions in clinical trials"]

long term: ["Safety data beyond 12 weeks remains limited; extended use requires monitoring"]

sequence: D-Arg-Dmt-Lys-Phe-NH2

half life: Approximately 2.5 hours

degradation: Primarily metabolized by proteolytic enzymes present in the blood.

molecular weight: 1334.48

molecular formula: C62H91N13O13

tissue specificity: Primarily targets mitochondria across various tissues.

• Mitochondrial protein interaction landscape of SS-31.mechanismPMID 32554501 ↗
• Efficacy and Safety of Elamipretide in Primary Mitochondrial Myopathy: MMPOWER-3 RCT.clinicalPMID 37268435 ↗